Patent & Trade Mark
Cameron Smith
Cameron Smith

Level 14, 90 Collins St
Melbourne VIC 3000 AUSTRALIA
Tel +61 3 8618 4128
Fax +61 3 8618 4199
Recent Publications
29 Jul 2016
The Intellectual Property Office of Singapore (IPOS) recently set a higher bar for allowance of post-grant amendments. The change in practice follows decisions in Ship's Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pty Ltd & Ors [2015] SGHC 159 and more recently Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd [2016] SGHC 106 where the Singapore High Court affirmed the guidelines for allowance of post-grant amendments set down in the UK.

19 Oct 2015
The Australian Patent Office proposes to exclude nucleic acids coding for polypeptides from patentability and retain patent eligibility for most other naturally occurring products, such as antibodies, polypeptides and stems cells. The proposal from IP Australia has issued in light of the High Court of Australia’s ruling that an isolated nucleic acid, coding for a mutant BRCA1 protein, is not a "patentable invention".

13 Aug 2014
Before the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 was enacted, the Australian Patent Office expressed its intent to crack down on extensions of time to file evidence in patent oppositions. Now, over a year since the associated regulations came into force, it is clear that obtaining such an extension will be difficult.
Cameron works closely with members of the local biotechnology community to manage their IP portfolios and develop their patent strategy.  Clients range from large publicly listed biotechnology companies to smaller ‘start-up’ companies and university commercialisation bodies.

Cameron has completed a bachelor of Biotechnology (honours) and has a PhD in molecular biology.  Cameron’s honours research project investigated neuronal changes that occur during chronic heart failure development and how these changes might be targeted to slow or arrest the progression of this disease.

During his honours year, Cameron also won the Nick McClure Prize in Enterprise Management, graduating top of his class in a course designed to develop the skills required for the commercialisation of technology via a ‘start-up’ biotechnology company.

Cameron’s PhD research focused on a class of small RNA molecules known as microRNA’s.  His studies investigated the role of microRNA’s in an upper gastrointestinal disease sequence characterised by its systematic progression from gastroesophageal reflux disease (GORD) to Barrett’s oesophagus and oesophageal cancer.  His research projects focused on investigating microRNA mediated mechanisms for cancer development, in addition to characterising microRNAs as useful diagnostic and prognostic biomarkers.

Cameron is a registered Australian Patent and Trade Marks Attorney.


  • Bachelor of Biotechnology (Honours) Medical and Pharmaceutical Biotechnology
  • Doctor of Philosophy (PhD), Biochemistry and Molecular Biology

Areas of Interest

  • Pharmaceutical and Agricultural Biotechnology
  • Molecular and Cellular Biology
  • Tumour Biology
  • Genetics
  • Biochemistry
  • Gastrointestinal Pathologies
  • In vivo Models
  • Biomarkers
  • Small RNA Molecules
  • microRNAs
  • Small molecule biochemistry
  • Commercialisation

Industry Focus

Professional Affiliations

  • Member of the Institute of Patent and Trade Mark Attorneys of Australia
  • Member of the Intellectual Property Society of Australia and New Zealand
  • Member of the Progression of Barrett's Oesophagus to Cancer Network (PROBE-NET)
  • Member of the Flinders Centre for Cancer Prevention and Control
  • Member of the Flinders Centre for Neuroscience